An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy Study of MK0928 15 mg and 10 mg in the Treatment of Adult Outpatients With Primary Insomnia

The purpose of this study is to evaluate the safety and effectiveness of MK0928 for insomnia (a sleep disorder).

Inclusion Criteria:

• Adult outpatients who are between the ages of 18 and 64

Exclusion Criteria:

• Adults who do not have a diagnosis of insomnia (a sleep disorder)